Beta-Blocker Influences on Inflammatory and Neural Responses to Stress

What this Trial Is About

Researchers are investigating how psychological stress leads to changes in inflammation that may increase the risk of cardiovascular disease. This study focuses on understanding the role of beta-adrenergic signaling, a molecular pathway involved in stress responses, by examining how blocking this pathway affects brain activity and inflammatory responses. The study combines neuroimaging and pharmacological methods to provide new insights into stress-related mechanisms and potential intervention targets. Participants will receive either a single oral dose of 40 mg propranolol, a non-selective beta-adrenergic receptor blocker, or an identical placebo capsule. The study uses a randomized, triple-blind design to compare the effects of propranolol versus placebo on neural and inflammatory responses to social stress. This design aims to causally link beta-adrenergic signaling with changes in inflammation and brain activity. During the study, participants will undergo social stress tasks while researchers measure changes in inflammatory markers, such as interleukin-6 and inflammatory gene expression, at specified times after drug administration and stress exposure. The study includes assessments of neural responses via neuroimaging and careful monitoring of participants' health and adherence. The total participation period extends from baseline measurements through 90 minutes post-stress to capture these responses.

Beta-Blocker Influences on Inflammatory and Neural Responses to Stress